ALK plus advanced NSCLC New ALK Inhibitor extends Sequence Options

被引：0
|
作者：
Freye, Reimund
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷 / 11期
关键词：
D O I：
10.1159/000494601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：720 / 720
页数：1
相关论文
共 50 条
  • [1] Alectinib superior to chemotherapy in advanced ALK plus NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (06): : E285 - E285
  • [2] Brigatinib: A Review in ALK-Inhibitor Naive Advanced ALK-Positive NSCLC
    Hoy, Sheridan M.
    DRUGS, 2021, 81 (02) : 267 - 275
  • [3] Genotypic Characteristics and Resistance Mutations in Advanced ALK plus NSCLC: The ALK-PATHFINDER Study
    Lopez Castro, R.
    Insa Molla, A.
    Esteban Gonzalez, E.
    Gomez Rueda, A.
    Isla Casado, D.
    Barneto Aranda, I.
    Bayona Anton, C.
    Majem Tarruella, M.
    Peralta Munoz, S.
    Garcia Campelo, R.
    Bosch Barrera, J.
    Juan Vidal, O. J.
    Bernabe Caro, R.
    Vicente Baz, D.
    Gordo Flores, R.
    Carrizo Mijarra, N.
    Ferrer Sanchez, I.
    Lopez Munoz, M. E.
    Ponce Aix, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E13 - E14
  • [4] Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC
    Sheridan M. Hoy
    Drugs, 2021, 81 : 267 - 275
  • [5] Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC
    Thomas, M.
    Wolf, J.
    Schuler, M.
    Goldwasser, M.
    Boral, A.
    Shaw, A. T.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 89 - 90
  • [6] ALK Inhibitor Sequencing and Outcomes Among ALK-Positive (ALK plus ) NSCLC Patients in the US Community Oncology Setting
    Waterhouse, D.
    Espirito, J.
    Chioda, M.
    Baidoo, B.
    Mardekian, J.
    Robert, N.
    Masters, E.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S560
  • [7] Advanced ALK plus NSCLC New Follow-up Data on 3rd Generation ALK-TKI
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (06)
  • [8] NSCLC New Therapy Options for ALK- positive Patients
    Kessing, Richard
    PNEUMOLOGIE, 2015, 69 (09): : 560 - 560
  • [9] Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.
    Shaw, Alice Tsang
    Mehra, Ranee
    Kim, Dong-Wan
    Felip, Enriqueta
    Chow, Laura Quan Man
    Camidge, D. Ross
    Tan, Daniel Shao-Weng
    Vansteenkiste, Johan F.
    Sharma, Sunil
    De Pas, Tommaso
    Wolf, Juergen
    Katayama, Ryohei
    Lau, Yi-Yang Yvonne
    Goldwasser, Meredith
    Boral, Anthony
    Engelman, Jeffrey A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Brigatinib Effective in ALK plus NSCLC
    Leslie, Mitch
    CANCER DISCOVERY, 2017, 7 (01) : 4 - 5
12345